Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Beyond Vaccines: Clinical Status of Prospective COVID-19 Therapeutics
Sriram Kumar, Duygu Merve Çalışkan, Josua Janowski, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 25

Showing 25 citing articles:

Analysis of post COVID-19 condition and its overlap with myalgic encephalomyelitis/chronic fatigue syndrome
Olga Sukocheva, Rebekah Maksoud, Narasimha M. Beeraka, et al.
Journal of Advanced Research (2021) Vol. 40, pp. 179-196
Open Access | Times Cited: 139
Oral antiviral treatments for COVID-19: opportunities and challenges
Laila Rahmah, Sunny O. Abarikwu, Amanuel Godana Arero, et al.
Pharmacological Reports (2022) Vol. 74, Iss. 6, pp. 1255-1278
Open Access | Times Cited: 70
Hypericum perforatum and Its Ingredients Hypericin and Pseudohypericin Demonstrate an Antiviral Activity against SARS-CoV-2
Fakry F. Mohamed, Darisuren Anhlan, Michael Schöfbänker, et al.
Pharmaceuticals (2022) Vol. 15, Iss. 5, pp. 530-530
Open Access | Times Cited: 39
Virus Infection and Systemic Inflammation: Lessons Learnt from COVID-19 and Beyond
Aileen Faist, Josua Janowski, Sriram Kumar, et al.
Cells (2022) Vol. 11, Iss. 14, pp. 2198-2198
Open Access | Times Cited: 23
Identification of Hypericin as a Candidate Repurposed Therapeutic Agent for COVID-19 and Its Potential Anti-SARS-CoV-2 Activity
Aline da Rocha Matos, Bráulia Costa Caetano, João Luiz de Almeida Filho, et al.
Frontiers in Microbiology (2022) Vol. 13
Open Access | Times Cited: 22
COVID-19 symptoms are reduced by targeted hydration of the nose, larynx and trachea
Carolin Elizabeth George, G. Scheuch, Ulf Seifart, et al.
Scientific Reports (2022) Vol. 12, Iss. 1
Open Access | Times Cited: 21
What’s new in flow biocatalysis? A snapshot of 2020–2022
Michele Crotti, Marina Simona Robescu, Juan M. Bolívar, et al.
Frontiers in Catalysis (2023) Vol. 3
Open Access | Times Cited: 11
Some natural compounds and their analogues having potent anti- SARS-CoV-2 and anti-proteases activities as lead molecules in drug discovery for COVID-19
Biswanath Dinda, Manikarna Dinda, Subhajit Dinda, et al.
European Journal of Medicinal Chemistry Reports (2022) Vol. 6, pp. 100079-100079
Open Access | Times Cited: 17
Current clinical status of new COVID-19 vaccines and immunotherapy
Diksha Nagpal, Shakti Nagpal, Deepak Kaushik, et al.
Environmental Science and Pollution Research (2022)
Open Access | Times Cited: 14
COVID‐19: An Overview of SARS‐CoV‐2 Variants—The Current Vaccines and Drug Development
Narjess Bostanghadiri, Pardis Ziaeefar, Morvarid Golrokh Mofrad, et al.
BioMed Research International (2023) Vol. 2023, Iss. 1
Open Access | Times Cited: 8
Perceptions towards COVID-19 Vaccines and Willingness to Vaccinate in Nepal
Deepak Subedi, Saurav Pantha, S Subedi, et al.
Vaccines (2021) Vol. 9, Iss. 12, pp. 1448-1448
Open Access | Times Cited: 17
A Peek into Pandora’s Box: COVID-19 and Neurodegeneration
Abhishek Chandra, Ashu Johri
Brain Sciences (2022) Vol. 12, Iss. 2, pp. 190-190
Open Access | Times Cited: 11
Repurposing Antifungals for Host-Directed Antiviral Therapy?
Sebastian Schloer, Jonas Goretzko, Ursula Rescher
Pharmaceuticals (2022) Vol. 15, Iss. 2, pp. 212-212
Open Access | Times Cited: 9
Safety and immunogenicity of inactivated COVID-19 vaccination in adult rheumatic patients in South China: a prospective study
Huiqiong Zeng, Hanjiang Liu, Zhi Liu, et al.
Human Vaccines & Immunotherapeutics (2022) Vol. 18, Iss. 5
Open Access | Times Cited: 9
Novel ACE2 fusion protein with adapting activity against SARS-CoV-2 variants in vitro
Latifa Zekri, Natalia Ruétalo, Mary Christie, et al.
Frontiers in Immunology (2023) Vol. 14
Open Access | Times Cited: 4
Nationwide Analysis of the Clinical Outcomes of Patients Admitted With COVID-19 Infection With Myocarditis and Racial Disparities in Mortality
Harmon R. Cannon, Aniesh Bobba, Rahul Shekhar, et al.
Current Problems in Cardiology (2022) Vol. 48, Iss. 2, pp. 101481-101481
Open Access | Times Cited: 7
Divergent Antibody Repertoires Found for Omicron versus Wuhan SARS-CoV-2 Strains Using Ig-MS
Eleonora Forte, Benjamin J. Des Soye, Rafael D. Melani, et al.
Journal of Proteome Research (2022) Vol. 21, Iss. 12, pp. 2987-2997
Open Access | Times Cited: 6
Controlling the Burden of COVID-19 by Manipulating Host Metabolism
Logan Miller, Engin Berber, Deepak Sumbria, et al.
Viral Immunology (2021) Vol. 35, Iss. 1, pp. 24-32
Open Access | Times Cited: 7
Improved survival of SARS COV-2-infected K18-hACE2 mice treated with adenosine A2AR agonist
Barbara J. Mann, Preeti Chhabra, Mingyang Ma, et al.
Heliyon (2023) Vol. 9, Iss. 8, pp. e19226-e19226
Open Access | Times Cited: 2
Small molecule RAF265 as an antiviral therapy acts against HSV‐1 by regulating cytoskeleton rearrangement and cellular translation machinery
Cui‐Cui Li, Xiaojing Chi, Jing Wang, et al.
Journal of Medical Virology (2022) Vol. 95, Iss. 1
Closed Access | Times Cited: 4
Multivalent Vaccine Strategies in Battling the Emergence of COVID-19 Variants
Paul C. Guest
Methods in molecular biology (2022), pp. 21-36
Closed Access | Times Cited: 3
Alpha to Omicron (Variants of Concern): Mutation Journey, Vaccines, and Therapy
Mohamad Hamad, Dana M.H. AlKhamach, Lujain Majed Alsayadi, et al.
Viral Immunology (2023) Vol. 36, Iss. 2, pp. 83-100
Closed Access | Times Cited: 1
Management of the COVID crisis in Reunion Island (SW Indian Ocean): representations of COVID-19 and acceptance of public health measures
Amandine Junot, Pascale Chabanet, Valéry Ridde
Health Psychology and Behavioral Medicine (2023) Vol. 11, Iss. 1
Open Access | Times Cited: 1
Adenosine A2A Receptor (A2AR) agonists improve survival in K28-hACE2 mice following SARS CoV-2 infection
Barbara J. Mann, Preeti Chhabra, Mingyang Ma, et al.
bioRxiv (Cold Spring Harbor Laboratory) (2022)
Open Access | Times Cited: 1
Strategies for Working With Parents With Vaccination Hesitancy
Joan C. Kirui, Desi M. Newberry, Katie Harsh
Neonatal Network The Journal of Neonatal Nursing (2023) Vol. 42, Iss. 5, pp. 254-263
Closed Access
Page 1

Scroll to top